Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Imatinib in CML
NCT04883125Phase 2Completed
- Sponsor
- Mansoura University
- Start
- Jan 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pioglitazone in chronic myeloid leukemia (CML) (2 arms), sponsored by Mansoura University. Primary endpoints: Rate of major molecular response (MMR) at 12 months and Expression levels of stemness genes (HIF2a, CITED2) at 6 months. Started Jan 2018; status: completed.
02
Drugs
pioglitazone
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04883125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883125.